Drugs / Birth dose hepatitis B vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03897946 | Aug 2019 → Feb 2021 | hepatitis B virus infection | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Birth dose hepatitis B vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03897946 ↗ |
| Known as | HepB-BD | “The WHO recommends hepatitis B birth-dose vaccination (HepB-BD), but it is not routinely given in most sub-Saharan African countries.” PMID 39314125 ↗ Sep 2024 |
| Modality | Vaccine | “HBV vaccine has been incorporated into pediatric immunization schedules worldwide for nearly two decades” NCT03897946 ↗ |